



March 19, 2025

To Whom It May Concern:

Company Name: KIRIN HOLDINGS COMPANY, LIMITED
 Name and Title of Representative: Takeshi Minakata, President & COO
 Code Number: 2503 (Tokyo Stock Exchange, Prime Section)
 Head Office:
 4-10-2, Nakano, Nakano-ku, Tokyo 164-0001, Japan
 Name and Title of Contact Person:
 Hidefumi Matsuo General Manager of Finance Department
 Telephone Number: +81-3-6837-7015

[Updated / Updated of Numerical Data] Notice of partial revision of the Summary of Consolidated Financial Results for the Year Ended December 31, 2024 (under IFRS)

Kirin Holdings Company, Limited today announced the following revision of the Summary of Consolidated Financial Results for the Year Ended December 31, 2024 (under IFRS) released on February 14, 2025 as listed below. As numerical data has been updated, the updated numerical data is submitted. The revised parts are underlined.

1. The Revision

The Summary of Consolidated Financial Results for the Year Ended December 31, 2024
 Pages 22 and 23

3. CONSOLIDATED FINANCIAL STATEMENTS

(5) NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Segment Information) (3) Information on reportable segments

<Before revision>

At and for the year ended December 31, 2023

	Reportable segment				Others (Note 1)	Adjustment (Note 2)	Consolidated
	Alcoholic Beverages	Non-alcoholic Beverages	Pharmaceu- ticals	Health Science			
Segment assets	<u>1,331,859</u>	<u>287,563</u>	971,375	<u>472,230</u>	<u>532,349</u>	<u>(725,791)</u>	2,869,585
Other items							
Depreciation and amortization	35,296	12,719	20,938	5,172	3,803	9,299	87,227
Impairment losses (excluding financial assets)	2,476	—	10,843	16,668	—	—	29,987
Equity-accounted investees	229,501	—	12,357	128,863	—	—	370,720
Capital expenditures	39,098	24,242	33,273	10,127	2,723	10,283	119,745

(¥ millions)

At and for the year ended December 31, 2024

	Reportable segment				Others (Note 1)	Adjustment (Note 2)	Consolidated
	Alcoholic Beverages	Non-alcoholic Beverages	Pharmaceu- ticals	Health Science			
Segment assets	<u>1,368,009</u>	326,366	<u>1,016,051</u>	<u>636,950</u>	<u>392,559</u>	<u>(385,776)</u>	3,354,159
Other items							
Depreciation and amortization	36,070	12,778	24,780	8,937	3,753	9,383	95,702
Impairment losses (excluding financial assets)	3,902	—	2,060	7,427	—	—	13,389
Equity-accounted investees	213,065	—	3,139	—	—	—	216,205
Capital expenditures	39,024	20,897	109,474	6,683	7,172	10,358	193,607

<After revision>

At and for the year ended December 31, 2023

	Reportable segment				Others (Note 1)	Adjustment (Note 2)	Consolidated
	Alcoholic Beverages	Non-alcoholic Beverages	Pharmaceu- ticals	Health Science			
Segment assets	<u>1,346,528</u>	<u>287,417</u>	971,375	<u>473,664</u>	<u>510,397</u>	<u>(719,795)</u>	2,869,585
Other items							
Depreciation and amortization	35,296	12,719	20,938	5,172	3,803	9,299	87,227
Impairment losses (excluding financial assets)	2,476	—	10,843	16,668	—	—	29,987
Equity-accounted investees	229,501	—	12,357	128,863	—	—	370,720
Capital expenditures	39,098	24,242	33,273	10,127	2,723	10,283	119,745

At and for the year ended December 31, 2024

	Reportable segment				Others (Note 1)	Adjustment (Note 2)	Consolidated
	Alcoholic Beverages	Non-alcoholic Beverages	Pharmaceu- ticals	Health Science			
Segment assets	<u>1,367,470</u>	326,366	<u>1,012,722</u>	<u>764,058</u>	<u>362,385</u>	<u>(478,841)</u>	3,354,159
Other items							
Depreciation and amortization	36,070	12,778	24,780	8,937	3,753	9,383	95,702
Impairment losses (excluding financial assets)	3,902	—	2,060	7,427	—	—	13,389
Equity-accounted investees	213,065	—	3,139	—	—	—	216,205
Capital expenditures	39,024	20,897	109,474	6,683	7,172	10,358	193,607

- END -